Invivoscribe, Inc.
5
1
1
2
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 5 trials
100.0%
+13.5% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 2 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (5)
The Use of Residual De-identified Specimens and/or Samples From Patients for Clinical Research
Role: lead
Pivotal, Clinical Study for the Accuracy Evaluation of the IdentiClone Dx TRG Assay
Role: lead
Pivotal, Clinical Study for the Accuracy Evaluation of the IdentiClone Dx IGH Assay
Role: lead
Minimal Residual Disease in Peripheral T-cell Lymphoma
Role: collaborator
The Use of Peripheral Blood Specimens From Patients Suspected of Having SARS-CoV-2 Infections in Research Studies Intended to Support the Development of COVID-19 Detection Methods, Treatments, and/or Vaccines
Role: lead
All 5 trials loaded